Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Panelists discuss how physicians determine when to escalate from conservative management to complement inhibitor therapy in patients with C3 glomerulopathy (C3G), considering factors like proteinuria levels, hematuria persistence, biopsy activity scores, and the critical need for improved diagnostic capabilities to guide targeted treatment selection.

When Is It Time to Escalate? Navigating C3G Treatment Decisions

Panelists discuss how improved understanding of C3 glomerulopathy (C3G) pathobiology has led to multiple clinical trials targeting complement pathways, with considerations for efficacy measurement through proteinuria reduction and kidney biopsies, while emphasizing the importance of vaccination and patient education to manage safety concerns associated with complement inhibitors.

Ongoing Clinical Trials in C3G: Safety, Efficacy, and Future Directions

The month in review spotlights renal FDA news and novel research about CKD and social determinants of health in kidney care.

Nephrology Month in Review: April 2025

Panelists discuss how educating physicians and patients about C3 glomerulopathy (C3G) presents unique challenges due to its rarity, complexity, and the critical role of renal pathologists in diagnosis while emphasizing the growing importance of understanding the complement system as new targeted therapies emerge.

Strength in Numbers: Raising Awareness of C3G and Other Rare Diseases

Panelists discuss how eculizumab initially provides short-term benefits for patients with C3 glomerulopathy (C3G) through C5a inhibition and anti-inflammatory effects but often loses efficacy over time as the disease progresses due to inadequate control at the C3 convertase level, suggesting newer complement-targeting therapies may offer better long-term management than C5 blockade.

Managing C3G: Comparing Conservative and Emerging Targeted Treatment Strategies

Norouzi reflects on significant advances in glomerular disease from Q1 and looks ahead to what the rest of 2025 may have to offer.

What’s New and What’s Next in Glomerular Disease Care, with Sayna Norouzi, MD

Panelists discuss how treatment approaches for C3 glomerulopathy (C3G) have evolved from nonspecific immunosuppression to targeted complement inhibition, with the recent FDA approval of iptacopan marking a significant advancement in disease management.

Personalizing C3G Treatment: Insights From Experienced Clinicians

Panelists discuss how C3 glomerulopathy (C3G) is triggered by factors like infections or pregnancy that activate the alternative pathway in genetically predisposed individuals, presenting with diverse clinical manifestations that often overlap with other glomerular diseases, making diagnosis challenging without kidney biopsy.

The Cost of Diagnostic Delay of C3G Across Age Groups

C3G Diagnosis: Overlapping Symptoms, Triggers, and Evolving Challenges

Panelists discuss how C3 glomerulopathy is an ultrarare glomerular disease characterized by alternative pathway complement dysregulation, which can be caused by either genetic defects or acquired abnormalities like antibodies against regulatory proteins.

Understanding C3G: Pathophysiology and Genetic Factors

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

C3 Glomerulopathy